Speaker illustration

Doctor Silvia Cantoni

R&D Chiesi Farmaceutici S.P.A., Parma (Italy)

Member of:

European Society of Cardiology

The selective rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates monocrotaline-induced pulmonary hypertension

Event: ESC Congress 2017

Topic: Chronic pulmonary hypertension

Session: Understanding the pulmonary circulation

Thumbnail

Hemodynamic and anti-remodelling effect of the rho kinase inhibitor y-27632 in monocrotaline pulmonary arterial hypertension rat model

Event: ESC Congress 2016

Topic: Chronic pulmonary hypertension

Session: Basic mechanisms in pulmonary hypertension

Thumbnail